5.1.4 Aminoglycosides

  • Injection 20mg/2ml, 40mg/2ml, 80mg/2ml
  • Intrathecal injection 5mg/ml


  1. For patients with Cystic Fibrosis (CF): treatment should only be prescribed by secondary care
  2. Blood level monitoring is mandatory for continued therapy.
  3. Gentamicin may be prescribed for nebulisation under recommendation from an appropriate secondary care consultant.
  4. It should be noted that nebulisation of gentamicin is an established but unlicensed use, see here for information on unlicensed/ off-label use.
  • Injection 40mg/ml, 1ml (40mg) vial, 2ml (80mg) vial
  • Nebuliser solution 60mg/ml (300mg in 5ml), 75mg/ml (300mg in 4ml)
  • TOBI® Podhaler (dry powder for inhalation) 28mg/capsule with inhaler device


  1. For patients with CysticFibrosis (CF): treatment should only be prescribed by secondary care
  2. NICE TA276: Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis (March 2013):
    1. Tobramycin DPI (TOBI Podhaler) is recommended as an option for treating chronic pulmonary infection caused by Pseudomonas aeruginosa in people with CF only if the criteria within the NICE TA are met
  • Injection 100mg/2ml, 500mg/2ml


  1. For use within University Hospitals Plymouth NHS Trust
Neomycin sulphate
  • Tablets 500mg


Home > Formulary > Chapters > 5. Infections > 5.1 Antibacterial drugs > 5.1.4 Aminoglycosides


  • First line
  • Second line
  • Specialist
  • Hospital